Advertisement
News
Subscribe to MDT Magazine News

Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting

December 6, 2010 4:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 6, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the...

TOPICS:

CareFusion to Provide Pyxis® Point-of-Care Products to Veterans Affairs Hospitals Nationwide

December 6, 2010 4:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 6, 2010 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today announced the award of the Pyxis® point-of-care verification suite of products across 153 U.S. Department of Veteran Affairs (VA) medical centers and 17 outpatient centers. (Logo:...

TOPICS:

Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System

December 6, 2010 4:33 am | by Bio-Medicine.Org | Comments

MIAMI, Dec. 6, 2010 /PRNewswire-USNewswire/ -- Fuisz Pharma today released photos of what the clinician will see in a standard nasal otoscopic exam in the case of a patient abusing an opioid, like Oxycontin® and others, through snorting. A food safe dye included in the tablet creates...

TOPICS:
Advertisement

NIH-sponsored panel issues comprehensive US food allergy guidelines

December 6, 2010 4:32 am | by EurekAlert | Comments

(NIH/National Institute of Allergy and Infectious Diseases) An expert panel sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has issued comprehensive US guidelines to assist health care professionals in diagnosing food...

TOPICS:

Purdue Pharma L.P. Re-launches Partners Against Pain Website

December 6, 2010 2:33 am | by Bio-Medicine.Org | Comments

STAMFORD, Conn., Dec. 6, 2010 /- Purdue Pharma L.P. unveiled an enhanced version of its popular educational website www.PartnersAgainstPain.com , making it is easier for healthcare professionals, people with pain and their caregivers to access valuable pain management information,...

TOPICS:

PAREXEL Opens Clinical Logistics Facilities in Singapore and Russia

December 6, 2010 2:32 am | by Bio-Medicine.Org | Comments

BOSTON, Dec. 6, 2010 /- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced that it has opened two new Clinical Logistics Services facilities in emerging regions for biopharmaceutical development.   PAREXEL's new...

TOPICS:

ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering

December 6, 2010 2:32 am | by Bio-Medicine.Org | Comments

SKILLMAN, N.J., Dec. 6, 2010 /- ConvaTec Healthcare, a world-leading developer, manufacturer and marketer of innovative medical technologies for community and hospital care, today announced that in connection with a refinancing of its debt under its existing senior secured and mezzanine...

TOPICS:

China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Pr...

December 5, 2010 10:33 pm | by Bio-Medicine.Org | Comments

BEIJING, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its wholly-owned subsidiaries, Beijing GP Medical Technologies Co., Ltd. ("GP...

TOPICS:
Advertisement

Study finds family acceptance of LGBT youth protects against depression, substance abuse, suicide

December 5, 2010 8:37 pm | by EurekAlert | Comments

(San Francisco State University) Researchers have established a clear link between accepting family attitudes and behaviors towards their lesbian, gay, bisexual and transgender (LGBT) children and significantly decreased risk and better overall health in adulthood. The study shows...

TOPICS:

Lasers Give Scientists Close-Up View of the Skin

December 5, 2010 8:34 pm | by Massachusetts Institute of Technology | Comments

The new technique could lead to an alternative to biopsies

TOPICS:

Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer

December 5, 2010 4:36 pm | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 5, 2010 /- Pfizer Inc. (NYSE: PFE ) today announced that its Board of Directors has elected Ian C. Read, 57, currently head of the Company's global biopharmaceutical operations, as President, Chief Executive Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, who...

TOPICS:

Genentech: positive results from cancer drug study

December 5, 2010 1:45 pm | by The Associated Press | Comments

SOUTH SAN FRANCISCO, Calif. (AP) — Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday announced positive results from the late-stage study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma.The study examined patients with follicular...

Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765

December 5, 2010 1:33 pm | by Bio-Medicine.Org | Comments

ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 5, 2010 /- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced data from three Chronic Lymphocytic Leukemia (CLL) presentations at the American Society of Hematology (ASH) Annual Meeting describing the Btk-selective inhibitor PCI-32765.  Two...

TOPICS:

Northern wildfires threaten runaway climate change, study reveals

December 5, 2010 9:33 am | by EurekAlert | Comments

(University of Guelph) This study reveals that fires in the Alaskan interior have become more severe in the last decade, resulting in more carbon being released than is being stored. About half the world's soil carbon is locked in northern permafrost and peatland soils. The increased...

TOPICS:

Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting

December 4, 2010 8:35 am | by Bio-Medicine.Org | Comments

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2010 /- Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading